Recombinant Human Brain Derived Neurotrophic Factor (BDNF).

Detect Brain Derived Neurotrophic Factor using this Anti-Brain Derived Neurotrophic Factor Antibody validated for use in WB, IH.

Immunohistochemistry: 1:1,000 (see suggested protocol).

Immunoblotting:1:1,000; we recommend preparing the BDNF samples for western blot by the method of Katoh-Semba (1997) because BDNF is not easily extracted in standard buffers. Dissected tissues should be homogenized in 10 volumes of 100mM phosphate buffer containing 1mM EDTA, 2M guanidine hydrochloride (pH7.2), and three protease inhibitors, 10mM N-ethylmaleimide, 0.36mM pepstatin, and 1mM PMSF. Homogenates are then sonicated and centrifuged at 46K x g for 30 minutes at 4C.

BIOLOGICAL ACTIVITY: Neutralizes BDNF, but not other neurotrophins.

Optimal working dilutions must be determined by end user.

Research Category
Neuroscience

Research Sub Category
Neurochemistry & Neurotrophins

Neuroinflammation & Pain

Brain Derived Neurotrophic Factor (BDNF). By dot blot, less than 1% cross-reactivity against NGF, NT3 or NT4.

SPECIES REACTIVITIES: Rat and human. Other species not yet tested. It is likely that the antibody will also work on mouse and porcine due to sequence homology.

Lyophilized, no preservatives. Reconstitute with 50 μL of sterile distilled water.

Maintain lyophilized material at -20 to -70°C for up to 12 months. After reconstitution maintain at -20°C in undiluted aliquots for up to 6 months. Avoid repeated freeze/thaw cycles. Glycerol (1:1) can be added for additional stability.

CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.